Literature DB >> 32418649

Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.

An-Du Zhang1, Xiao-Hua Su2, Gao-Feng Shi3, Chun Han1, Lan Wang1, Hui Liu1, Jun Zhang1, Ruo-Hui Zhang1.   

Abstract

BACKGROUND AND
OBJECTIVE: To compare the survival of esophageal squamous cell carcinoma (ESCC) patients who received chemoradiotherapy (CRT) or radiotherapy (RT) alone.
METHODS: A total of 753 well-matched patients were enrolled. A total of 299 patients were treated with CRT, and 454 patients were treated with RT alone. Propensity score matching (PSM) was performed with the R project. The Kaplan-Meier method was used to calculate survival rates, and the log-rank test was used to assess differences in survival.
RESULTS: The response rate was 99.0% with CRT and 98.3% with RT alone (p = 0.651). The 1-, 3-, 5- and 10 year overall survival (OS) rates were as follows: 72.2, 40.1, 30.7 and 13.9% with CRT, 68.1, 35.2%, 23.3 and 12.5% with RT alone (p = 0.033); 73.4, 40.1, 31.0 and 16.1% with concurrent chemoradiotherapy (CCRT); and 68.1, 35.2, 23.3 and 12.5% with RT alone (p = 0.028). There was no significant difference in OS between the CCRT group and the sequential chemoradiotherapy (SCRT) group (p = 0.527). Consolidation chemotherapy (CCT) after CCRT led to a significant increase in the OS rate compared with no CCT after CCRT (p = 0.003). Compared with the OS of patients who received 1∼2 cycles of CCT, the OS of patients who received 3∼4 cycles of CCT was significantly improved (p = 0.011). Acute toxic effects were more severe in the CRT, but no significant differences in late reactions. CRT exhibited more appetite loss and fatigue symptoms than RT alone, and dysphagia of CRT relief more obviously. The CRT group had a significantly lower rate of local control failure than the RT alone group (p = 0.019).
CONCLUSIONS: For patients with ESCC, CRT led to a significantly improved OS compared to RT alone, and this trend was more obvious with CCRT. CCT after CCRT prolonged OS, especially in patients who received at least 2 cycles of CCT. CRT can reduce the deaths due to local control failure compared to RT alone.
Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoma; Chemoradiotherapy; Esophageal neoplasms; Overall survival; Squamous cell

Year:  2020        PMID: 32418649     DOI: 10.1016/j.arcmed.2020.04.013

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  7 in total

1.  Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma.

Authors:  Zhen-Yuan Zheng; Man-Yu Chu; Wan Lin; Ya-Qi Zheng; Xiu-E Xu; Yang Chen; Lian-Di Liao; Zhi-Yong Wu; Shao-Hong Wang; En-Min Li; Li-Yan Xu
Journal:  Cell Death Dis       Date:  2022-05-25       Impact factor: 9.685

2.  Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy.

Authors:  Junchao Qian; Youjiao Si; Ke Zhou; Yu Tian; Qisen Guo; Kaikai Zhao; Jinming Yu
Journal:  BMC Gastroenterol       Date:  2022-04-30       Impact factor: 2.847

3.  Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis.

Authors:  Xiaojie Xia; Zeyuan Liu; Qin Qin; Xiaoke Di; Zhaoyue Zhang; Xinchen Sun; Xiaolin Ge
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

4.  Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jianing Wang; Linlin Xiao; Shuai Wang; Qingsong Pang; Jun Wang
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

5.  Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study.

Authors:  Chen-Yuan Lin; Ming-Yu Lien; Chi-Ching Chen; Hsin-Yuan Fang; Yu-Sen Lin; Chien-Kuang Chen; Jian-Xun Chen; Ting-Yu Lu; Tzu-Min Huang; Te-Chun Hsieh; Shung-Shung Sun; Chia-Chin Li; Chun-Ru Chien
Journal:  BMC Gastroenterol       Date:  2022-08-10       Impact factor: 2.847

6.  Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy.

Authors:  Xiaojie Xia; Mengxing Wu; Qing Gao; Xinchen Sun; Xiaolin Ge
Journal:  Curr Oncol       Date:  2022-09-02       Impact factor: 3.109

7.  Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.

Authors:  Ao Liu; Yalin Wang; Xin Wang; Liqiong Zhu; Yu Nie; Minghuan Li
Journal:  Radiat Oncol       Date:  2021-10-02       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.